Related Stocks: BAX , CVS , ZBH , MSFT , GOOGL ,

Related Stocks: GILD , BDX , PFE , ALNY , ZBH ,

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ: MOHO ) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ: ENVB ) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ: HSCS ) jumped 89.6% to close at $3.28. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares surged 85.6% to close at $4.51 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Eargo, Inc. (NASDAQ: EAR ) shares gained 75.6% to settle at $1.23.

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) gained 112.4% to $5.48. Eargo, Inc. (NASDAQ: EAR ) shares climbed 102.8% to $1.42. The company is scheduled to report Q2 earnings on Monday, August 8. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Applied DNA Sciences, Inc. (NASDAQ: APDN ) climbed 75.7% to $4.92 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. Kintara Therapeutics, Inc. (NASDAQ: KTRA ) gained 70% to $0.3013 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million. Ping Identity Holding Corp. (NYSE: PING ) shares climbed 59.8% to $27.92 after the company announced it will be acquired by Thoma Bravo for $28.50 per share in cash.

NeuroOne Medical Technologies (NMTC) entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet (ZBH) providing the company with a…

https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-135-at-stifel-432SI-2861045

https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-119-at-citi-432SI-2860908

Zimmer Biomet (ZBH) stock gained as much as 6.1% to $116.46 in Tuesday trading, after the medical device company reported Q2 results that beat estimates and raised its FY 2022…

Zimmer Biomet Holdings, Inc. (NYSE:NYSE:ZBH) Q2 2022 Earnings Conference Call August 2, 2022 8:30 a.m.

The global biosurgery market size was USD 12.4 Bn in 2021 and is anticipated to reach USD 21.2 Bn in 2031, growing at a rate [read full press release…]

Zimmer Biomet Holdings, Inc. (ZBH) shares are trading more than 5 percent on Tuesday morning trade after the company reported higher earnings for the second quarter and a boost in full-year outlook.

Zimmer Biomet Holdings Inc''s (NYSE: ZBH ) Q2 sales increased by 1% Y/Y to $1.78 billion (up 6% on a constant currency basis), beating the consensus of $1.72 billion. Adjusted EPS was $1.82, which exceeded the consensus of $1.65 and $1.51 a year ago. "Our performance in Q2 was well above our internal expectations due to stronger than … Full story available on Benzinga.com

WASHINGTON (dpa-AFX) - (Adds Outlook)Zimmer Biomet Holdings Inc. (ZBH) revealed a profit for its second quarter that increased from the same period last yearThe company''s bottom line came in at $1…

Zimmer Biomet Earnings, Revenue Beat in Q2

Zimmer Biomet Holdings Tops Q2 EPS by 18c; Bumps Guidance Slightly

Zimmer Biomet press release (ZBH): Q2 Non-GAAP EPS of $1.82 beats by $0.18.Revenue of $1.78B (-12.3% Y/Y) beats by $60M.FY2022 Outlook: Raises revenue outlook to (1.0)% - 1.0% vs

Second quarter net sales from continuing operations of $1.782 billion increased 1.0% and 6.0% on a constant currency1 basis Second quarter diluted earnings per share from continuing operations were $0.73; adjusted1 diluted earnings per share from continuing operations were $1.82 Company…

Zimmer Biomet (ZBH) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open.The consensus EPS Estimate is $1.64 (-13.7% Y/Y) and the consensus…

Zimmer Biomet (ZBH) and the Hospital for Special Surgery will form the HSS/Zimmer Biomet Innovation Center for Artificial Intelligence in Robotic Joint Replacement.

Some of the major players operating in the craniomaxillofacial devices industry are Johnson & Johnson, Stryker Corporation, Medtronic, Aesculap Implants Systems (B Braun Melsungen AG), and Zimmer Biomet. SELBYVILLE, Del., July 20, 2022 /PRNewswire/ -- The craniomaxillofacial devices market value is expected to reach USD 3 billion by 2030, according to a new research report by Global Market

Zimmer Biomet Holdings found using ticker (ZBH) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 145 and 114 calculating the mean target price we have 128.58. With the stocks previous close at 101.65 this indicates there is a potential upside of 26.5%. The 50 day MA is 112.3 and the 200 moving average now moves to 122.69. The market cap for the company is $21,693m. Visit the company website at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,440m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

The ZIMMER FOR SENATE INC successfully filed their F3N JULY QUARTERLY with the coverage period of 04/01/2022 to 06/30/2022 and a confirmation ID of FEC-1608448 *********CommitteeId: C00449074 | FilingId: 1608448 | FormType: F3N | CoverageFrom: 04/01/2022 | CoverageThrough: 06/30/2022 | ReportType: JULY QUARTERLY*********

ZimVie was spun out of Zimmer Biomet in March. See why we recommended investors to look for opportunities to accumulate ZIMV stock in the coming months.

WARSAW, Ind., July 5, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 2, 2022 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that…

Effective July 1, Indiana customers who pay an electric bill to one of the five Indiana investor-owned utilities — Duke Energy Indiana, Indiana Michigan Power, NIPSCO, CenterPoint (formerly known as Vectren), or AES Indiana (formerly known as Indianapolis Power & Light) — will no longer be allowed to participate in net metering when they install…

Zimmer Biomet this week announced it created an independent 501(c)(3) for its philanthropic, multi-disciplinary coalition Movement is Life. The new 501(c)(3) non-profit organization designation will allow the Warsaw, Indiana-based company to raise awareness of the impact of disparities on chronic disease management and quality of life among women, racial and ethnic minorities and women living […]

Pfizer Inc. (NYSE:PFE) and its partner BioNTech SE (Nasdaq:BNTX) profited handsomely from COVID-19 vaccine sales in 2021. The firms raked in more than $59 billion in combined sales of the Comirnaty vaccine.  The two companies have now announced a new vaccine supply agreement with the U.S. government worth $3.2 billion. Under the terms of the…

Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using […]